金斯瑞生物科技(01548.HK):傳奇生物將2024年年美國臨牀腫瘤學會及歐洲血液學協會年會公佈用於治療多發性骨髓瘤患者的CARVYKTI最新資料
格隆匯5月24日丨金斯瑞生物科技(01548.HK)發佈公吿,當地時間2024年5月23日,傳奇生物(NASDAQ:LEGN)在美國新澤西州薩默塞特宣佈, CARTITUDE臨牀開發計劃中評估CARVYKTI®(cilta-cel,西達基奧侖賽)治療多發性骨髓瘤患者的最新資料將在2024年美國臨牀腫瘤學會(ASCO)年會和2024年歐洲血液學協會(EHA)大會上公佈。
來自2期研究CARTITUDE-2的隊列D調查了在自體幹細胞移植(ASCT)一線治療後未達到完全緩解的患者單次輸注CARVYKTI®聯合或不聯合來那度胺維持治療的效果,該研究結果將以口頭報吿的形式在ASCO年會上首次展示,並在EHA會議上再次呈現。
來自3期研究CARTITUDE-4亞組分析的資料將以口頭報吿形式在ASCO年會上展示。該亞組分析比較了CARVYKTI® 與兩種標準療法在功能性高危多發性骨髓瘤患者中的療效。此外,基於細胞遺傳學風險的CARTITUDE-4亞組分析結果將以海報形式在EHA會議上展示。
傳奇生物首席執行官黃穎博士表示: “西達基奧侖賽CARTITUDE臨牀開發計劃的研究結果將為得益於該一次性治療的廣大患者提供重要見解。我們很高興與血液學和腫瘤學界分享我們的最新資料,同時我們致力於為患者帶來新的希望,並爭取朝一日能治癒多發性骨髓瘤。”
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.